TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02419040

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Barbotage
Description: A 18-gauge needle connected to a 5 ml syringe with 4 ml of saline solution will be used to puncture the calcification with freehand technique and under constant sonographic monitoring. With the tip of the needle placed in the center of the deposit, the calcification will be flushed. Finally, a new 21-gauge needle will be introduced into the subacromial-subdeltoid bursa and 9 ml of 1% Lidocain hydrochlorid and 1 ml (20 mg) of Triamcinolon will be injected into the subacromial-subdeltoid bursa. All patients will be instructed by a physioteherapist in home exercises.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid injection
Description: The tip of the 18-gauge needle will be placed in the soft parts outside of the rotator cuff and movements mimicking the lavage procedure will be performed. A lavage procedure usually takes 5 minutes and the same period of time will have to be used for the mimicking maneuver. Finally, a new 21-gauge needle will be introduced into the subacromial-subdeltoid bursa and 9 ml of 1% Lidocain hydrochlorid and 1 ml (20 mg) of Triamcinolon will be injected into the subacromial-subdeltoid bursa. All patients will be instructed by a physioteherapist in home exercises.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Lidocain injection (sham)
Description: The tip of the 18-gauge needle will be placed in the soft parts outside of the rotator cuff and movements mimicking the lavage procedure will be performed. A lavage procedure usually takes 5 minutes and the same period of time will have to be used for the mimicking maneuver. Finally, a new 21-gauge needle will be introduced into the subacromial-subdeltoid bursa and 10 ml of 1% Lidocain hydrochlorid will be injected into the subacromial-subdeltoid bursa. All patients will be instructed by a physioteherapist in home exercises.
Study: NCT04394052

Intervention type: DIAGNOSTIC_TEST
Intervention: MR imaging
Description: Medical imaging

Intervention type: DIAGNOSTIC_TEST
Intervention: MR imaging
Description: Medical imaging
Study: NCT00550420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone XR
Description: experimental drug
Study: NCT03468374

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lymphoscintigraphy
Description: Nuclear Medicine diagnostic device using radioactive material

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single Photon Emission Tomography
Description: Nuclear Medicine diagnostic device using fusion technique between SPECT and CT
Study: NCT04192799

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Direct admission
Description: Process of pediatric admission is through admission directly into the pediatric hospital medicine unit

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ED admission
Description: Process of pediatric admission is through the emergency department
Study: NCT05924451

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Immediate Loading
Description: Clinical and radiographic examination of the periimplant soft and hard tissue will be analysed by using gingival index, plaque index, and pocket depth immediately post operative.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate Loading
Description: Clinical and radiographic examination of the periimplant soft and hard tissue will be analysed by using gingival index, plaque index, and pocket depth immediately post operative.
Study: NCT03940586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letermovir oral granules
Description: Granules administered orally based on age, weight, and whether participant takes cyclosporin A as a concomitant medication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letermovir tablet
Description: Tablet administered orally based on age, weight, and whether participant takes cyclosporin A as a concomitant medication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letermovir intravenous
Description: Letermovir administered intravenously based on age, weight, and whether participant takes cyclosporin A as a concomitant medication.
Study: NCT02808663

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: fecal calprotectin concentration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood collection
Study: NCT01051999

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glutamine
Description: Oral glutamine powder

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: L-alanine
Description: L-alanine oral powder
Study: NCT04113538

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Intraocular injection of 2 ml (40mg/ml)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: Intraocular injection of 2 ml (40mg/ml)
Study: NCT03715673

Intervention type: DIAGNOSTIC_TEST
Intervention: von willebrand antigen and activity
Description: Measuring von Willebrand antigen and activity (VWF: RCo and VWF: CB)

Intervention type: DIAGNOSTIC_TEST
Intervention: von willebrand antigen and activity
Description: Measuring von Willebrand antigen and activity (VWF: RCo and VWF: CB)
Study: NCT01676311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huperzine A
Description: Huperzine A will be administered for 12 weeks as outlined in the Arm Description

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Arm (blinded randomization) for Huperzine A Intervention
Study: NCT04492007

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-Reported Outcomes-Informed Symptom Management System (PRISMS)
Description: Participants will receive personalized self-care information and guidance based on their symptoms and signs of complications (e.g., skin infection, fatigue) from the web-based telehealth PRISMS program. They will also have access through this website a peer support online forum that is moderated by a research nurse as well as professional support through videoconferencing/telephone from the research nurse and also their healthcare providers at the hospital(s) if they experience moderate to severe symptoms and/or abnormal sign (e.g., body temperature is greater than 98.6 C
Study: NCT04023318

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Lifestyle Intervention
Description: This program is grounded in data demonstrating the dysregulation across multiple domains and considerable life stressors experienced by this population. The central hypothesis is that by simultaneously ameliorating psychological dysregulation and directly targeting proinflammatory behaviors, ILI operates on multiple proposed mediators of poor treatment outcomes in this population, thereby enhancing treatment outcomes. As such, the overall framework emphasizes integration of self-regulation as it applies to both psychological functioning and weight control. Content will highlight the interconnectedness of mood, stress, eating and exercise behaviors, and risk for inflammation and disease. Each treatment session will present a combination of behavioral and psychological content, representing a truly integrated approach. Participants will meet for 75-minute group sessions weekly for months 1-2, followed by bi-weekly groups in months 3-4, for a total of 12 groups.
Study: NCT01890694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: 15 mg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 15 mg once daily

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Hepatic Encephalopathy Assessment
Description: The Number connection test, Digit symbol test, Constructional apraxia, Inhibitory control test, Repeatable Battery for the Assessment of Neuropsychological Status will be administered on Days 1, 2, 4, 6, and 8; discharge day; Weeks 1-4 post-discharge; and Months 2-6 post-discharge.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hepatic Encephalopathy Assessment
Description: The Number connection test, Digit symbol test, Constructional apraxia, Inhibitory control test, Repeatable Battery for the Assessment of Neuropsychological Status will be administered on Days 1, 2, 4, 6, and 8; discharge day; Weeks 1-4 post-discharge; and Months 2-6 post-discharge.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Quality of Life Assessment
Description: The SF-36 and Liver Disease Questionnaire will be administered on Day 1, Discharge day, Weeks 1-4 post-discharge, and months 2-6 post-discharge
Study: NCT05316207

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telenursing
Description: From the end of the first week after discharge to the end of the first month, patients were counseled over the phone during the home process. Complications were followed up.
Study: NCT01890694

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality of Life Assessment
Description: The SF-36 and Liver Disease Questionnaire will be administered on Day 1, Discharge day, Weeks 1-4 post-discharge, and months 2-6 post-discharge

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vital signs
Description: Vital signs (blood pressure, heart rate, respiration, temperature, weight, height) will be recorded at every visit.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vital signs
Description: Vital signs (blood pressure, heart rate, respiration, temperature, weight, height) will be recorded at every visit.
Study: NCT00486785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfuzosin
Description: Alfuzosin 10mg Once Daily for 24 weeks
Study: NCT01890694

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Blood laboratory tests
Description: Blood laboratory tests (chemistry, hematology, liver function, urine electrolytes, renin, and copeptin) will be recorded at every visit.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood laboratory tests
Description: Blood laboratory tests (chemistry, hematology, liver function, urine electrolytes, renin, and copeptin) will be recorded at every visit.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Ascites Evaluation
Description: Ascites will be assessed at every visit.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ascites Evaluation
Description: Ascites will be assessed at every visit.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Edema
Description: Edema will be assessed at every visit.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Edema
Description: Edema will be assessed at every visit.
Study: NCT03871569

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: bucco-dental teleexpertise
Description: A bucco-dental consultation remotely using telemedicine system
Study: NCT01665573

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-04457845
Description: Acquisition of conditioning Administration of drug Extinction of conditioning

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PF-04457845
Description: Acquisition of conditioning Administration of drug Extinction of conditioning

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Acquisition of conditioning Administration of placebo Extinction of conditioning

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Acquisition of conditioning Administration of placebo Extinction of conditioning
Study: NCT02174419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nalbuphine HCl ER tablets 90 mg BID
Description: nalbuphine HCl ER tablets 90 mg BID administered for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nalbuphine HCl ER tablets 180 mg BID
Description: nalbuphine HCl ER tablets 180 mg BID administered for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets BID
Description: Placebo tablets BID administered for 10 weeks
Study: NCT03406039

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Online CBT and MI
Description: The treatment condition will have access to 12 treatment modules and have 8-weeks to complete them. The content of all modules is derived from Cognitive Behavioural Therapy and Motivational Interviewing. Through module engagement, young adults will identify goals related to alcohol use and mood, learn strategies to cope with alcohol cravings, triggers, and social pressures, and learn how to prevent relapse. There will also be several modules to target anxiety and depression, focusing on strategies designed to help reduce negative thinking and worry, increase behavioural activation, and increase self-care (e.g., sleep hygiene).Participants will have immediate access to all modules, and it will be recommended that they work through the modules sequentially.
Study: NCT03014531

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: almond

Intervention type: OTHER
Group type: OTHER
Intervention: high-carbohydrate control food
Study: NCT02995967

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hydrodistention
Description: The hydrodistention will then be performed with the bladder filled at a pressure of 80 cm H2O and noted to be full as evidenced by no further influx of water into the bladder. This volume will be held in the bladder for 5 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin-A
Description: Intradetrusor injection of 100 units of botulinum toxin a
Study: NCT05061264

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abdominal wall reconstruction
Description: The repair of abdominal wall defects with polyvinylidene (PVDF) mesh
Study: NCT02951884

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aspiration
Description: A needle is placed into the knee joint and all of the blood that is in the joint is removed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aspiration
Description: A needle is placed into the knee joint and all of the blood that is in the joint is removed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: An injection of 20cc bupivacaine 0.5% with 1:200,00 epinephrine
Study: NCT04060654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublocade
Description: SUBLOCADE to be administered approximately every 4 weeks per local standard of care
Study: NCT01336608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate/Vilanterol
Description: Inhaled corticosteroid/long acting beta-agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilanterol
Description: Inhaled long acting beta-agonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00331773

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional 3D-CRT or IMRT
Description: Radiation therapy will be given once daily, five days a week, at 1.8 Gy per fraction, for 41 fractions and a total dose of 73.8 Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated 3D-CRT or IMRT
Description: Radiation therapy will be given once daily, five days a week, at 2.5 Gy per fraction, for 28 fractions and a total dose of 70 Gy.
Study: NCT02543268

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV-Batch #1
Description: Ad26.ZEBOV - Batch #1, live, replication incompetent vaccine, sterile suspension of 0.5 milliliter (mL) intramuscular (IM) injection of 5\*10\^10 viral particles on Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV-Batch #2
Description: Ad26.ZEBOV - Batch #2, live, replication incompetent vaccine, sterile suspension of 0.5 milliliter (mL) intramuscular (IM) injection of 5\*10\^10 viral particles on Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV-Batch #3
Description: Ad26.ZEBOV - Batch #3, live, replication incompetent vaccine, sterile suspension of 0.5 milliliter (mL) intramuscular (IM) injection of 5\*10\^10 viral particles on Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo
Description: MVA-BN-Filo- live replication incompetent vaccine, 0.5 mL IM injection of 1\*10\^8 Infectious Unit \[Inf. U.\] once on Day 57.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo
Description: MVA-BN-Filo- live replication incompetent vaccine, 0.5 mL IM injection of 1\*10\^8 Infectious Unit \[Inf. U.\] once on Day 57.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo
Description: MVA-BN-Filo- live replication incompetent vaccine, 0.5 mL IM injection of 1\*10\^8 Infectious Unit \[Inf. U.\] once on Day 57.
Study: NCT01591278

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulpotomy
Description: Comparison of two different pulp dressing agents
Study: NCT02543268

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One 0.5 ml IM injection of 0.9% saline once on Day 1 and Day 57.
Study: NCT02030834

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-19
Description: Single infusion of CART-19 cells administered by i.v. injection (total dose of 1 - 5 x108 CART-19 cells, calculated as a range of 2-50% transduced cells in total cells).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-19
Description: Single infusion of CART-19 cells administered by i.v. injection (total dose of 1 - 5 x108 CART-19 cells, calculated as a range of 2-50% transduced cells in total cells).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-19
Description: Single infusion of CART-19 cells administered by i.v. injection (total dose of 1 - 5 x108 CART-19 cells, calculated as a range of 2-50% transduced cells in total cells).
Study: NCT02614885

Intervention type: DEVICE
Intervention: RFA
Description: Radiofrequency ablation of the cavity walls of a simulated lumpectomy in the excised prophylactic mastectomy tissue.
Study: NCT00391937

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Articular Surface Replacement (ASR) hip prosthesis
Description: a DePuy ASR™ primary resurfacing femoral and acetabular component (DePuy International Ltd, Leeds, UK). The cement that will be used is one dose of DePuy SmartSet® GHV 40 gram, a high-viscosity cement with gentamycin (DePuy CMW, Blackpool, UK). Instrumentation includes standard ASR™ instruments and Ci™ Software for DePuy ASR™ System1.0.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Articular Surface Replacement (ASR) hip prosthesis
Description: a DePuy ASR™ primary resurfacing femoral and acetabular component (DePuy International Ltd, Leeds, UK). The cement that will be used is one dose of DePuy SmartSet® GHV 40 gram, a high-viscosity cement with gentamycin (DePuy CMW, Blackpool, UK). Instrumentation includes standard ASR™ instruments and Ci™ Software for DePuy ASR™ System1.0.
Study: NCT04630366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NST-1024
Description: NST-1024

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to NST-1024
Study: NCT03876158

Intervention type: DEVICE
Group type: OTHER
Intervention: Prometra II Programmable Pump system(Flowonix Medical)
Description: This valve gated Prometra II Programmable Pump system will be replacing prior peristaltic Synchromed II pump

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prometra II Programmable Pump system(Flowonix Medical)
Description: This valve gated Prometra II Programmable Pump system will be replacing prior peristaltic Synchromed II pump
Study: NCT02615873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Accordion Pill™ Carbidopa/Levodopa
Description: Accordion Pill™ Carbidopa/Levodopa Capsule 50/400mg , b.i.d or t.i.d or Accordion Pill™ Carbidopa/Levodopa Capsule 50/500mg , b.i.d or t.i.d
Study: NCT02780921

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prehabilitation

Intervention type: OTHER
Group type: OTHER
Intervention: nutritional support
Study: NCT05812222

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skin-to-Skin contact.
Description: Skin to skin contact: It is the laying of the newborn in the prone position on the mother's bare chest with only a diaper on.
Study: NCT02362594

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Pembrolizumab 200 mg administered intravenously (IV) on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Normal saline solution administered IV on Day 1 of each 21-day cycle
Study: NCT03233737

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: One spray CTY-5339-A
Description: Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredients: 14.0% Benzocaine (USP = 28 mg) and 2.0% Tetracaine Hydrochloride (USP = 4 mg). Administered in a single anesthetic spray.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: One spray CTY-5339-A
Description: Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredients: 14.0% Benzocaine (USP = 28 mg) and 2.0% Tetracaine Hydrochloride (USP = 4 mg). Administered in a single anesthetic spray.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: One spray CTY-5339-A
Description: Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredients: 14.0% Benzocaine (USP = 28 mg) and 2.0% Tetracaine Hydrochloride (USP = 4 mg). Administered in a single anesthetic spray.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: One spray CTY-5339-CB
Description: Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredient: 14.0% Benzocaine (USP = 28 mg). Administered in a single anesthetic spray.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: One spray CTY-5339-CB
Description: Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredient: 14.0% Benzocaine (USP = 28 mg). Administered in a single anesthetic spray.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: One spray CTY-5339-CB
Description: Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredient: 14.0% Benzocaine (USP = 28 mg). Administered in a single anesthetic spray.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: One spray CTY-5339-P
Description: Placebo. Metered spray bottle with ≈200 uL total spray volume. Contains no active ingredient (vehicle control).
Study: NCT01741909

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: education
Description: after a baseline period, shorter intravenous treatment will be promoted by mail, posters, lectures, and pharmacy monitoring of treatment
Study: NCT00665509

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent influenza subunit vaccine Influvac
Description: 3x 15mcg HA per 0.5 ml, trivalent one injection at Day 1